NEW YORK, May 21 (Reuters) - Abbott Laboratories Inc said on Wednesday its Humira medicine has maintained maximum effectiveness for a year or longer among roughly 29 percent of Crohn's disease ...

An open-label extension study of the Charm and Gain studies, performed in Abbott labs, demonstrate that patients with moderate-to-severe Crohn's disease who are treated with Humira (adalimumab) ...

The EC has approved broadening the use of Abbott’s TNF antagonist Humira® to include the treatment of moderately active Crohn’s disease in adult patients who have demonstrated an inadequate response ...

AbbVie's blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn's disease patients, potentially adding another arrow to the company's post-Humira quiver. The JAK inhibitor helped ...

As AbbVie comes under renewed scrutiny for its pricing and patenting strategies, the company is still working to build out the case for its next-gen immunology drugs Skyrizi and Rinvoq. In Crohn's ...

Johnson & Johnson’s (NYSE:JNJ) Stelara could become the #2 drug in the Crohn’s Disease market over the next few years. Crohn’s Disease causes inflammation of the digestive tract. J&J’s top selling ...